Throughout the first six months of 2022, we discover that the funding for all times sciences markets declined considerably in comparison with 2021. The pattern impacts all related life sciences subsectors of Biotech, HealthTech, and MedTech.
The financing volumes lowered by virtually one-third from EUR 9.5bn to EUR 6.6bn. Biotech and MedTech skilled essentially the most important reductions in funding exercise.
Apart from Sequence B corporations, this unfavourable pattern is constant throughout all funding phases and ranges from -20 % to -52 %.
Curiously, Sequence B HealthTech financing elevated by 85 %.